Updates from day five at Melbourne Park Men’s No 4 faces Italian qualifier on Rod Laver Arena Any thoughts? Get in touch with an email Tumaini Carayol was courtside for Djokovic’s round one exhibition. Djokovic seems to create history every time he steps on to a tennis court these days, and this occasion was no different. By simply lining up to the baseline against Martínez, Djokovic tied Roger Fe...
Updates from day five at Melbourne Park Men’s No 4 faces Italian qualifier on Rod Laver Arena Any thoughts? Get in touch with an email Tumaini Carayol was courtside for Djokovic’s round one exhibition. Djokovic seems to create history every time he steps on to a tennis court these days, and this occasion was no different. By simply lining up to the baseline against Martínez, Djokovic tied Roger Federer’s record of most main-draw appearances at the Australian Open (21), a tournament he has won a record 10 times, and Federer’s and Feliciano López’s record of most grand slam appearances (81). Continue reading...
Although broader equities performed well in 2025, volatility was significant, especially at the start of the year, partly due to the Trump administration's trade policies. The president imposed steep tariffs across the board, which many feared would harm corporations' financial results. The tariff situation is still evolving, and many companies are looking to find ways to overcome this potential t...
Although broader equities performed well in 2025, volatility was significant, especially at the start of the year, partly due to the Trump administration's trade policies. The president imposed steep tariffs across the board, which many feared would harm corporations' financial results. The tariff situation is still evolving, and many companies are looking to find ways to overcome this potential threat. That brings us to Johnson & Johnson (NYSE: JNJ) , a pharmaceutical leader that recently made headlines along those lines. Let's look into what these recent developments mean for Johnson & Johnson and whether the stock is worth investing in. Image source: Getty Images. On Jan. 8, Johnson & Johnson announced that it had reached a deal with the Trump administration to sell drugs at reduced prices in the country. In exchange, the healthcare giant will be exempt from tariffs . True, it's not ideal that Johnson & Johnson has to cut the prices of some of its medicines, but this could lead to increased sales volume that will somewhat offset the reduced price. Continue reading
Pepperstone Head of Research Chris Weston tells Bloomberg that while US equities may lag, the prospect of a Greenland deal has eased risk sentiment. (Source: Bloomberg)
Pepperstone Head of Research Chris Weston tells Bloomberg that while US equities may lag, the prospect of a Greenland deal has eased risk sentiment. (Source: Bloomberg)